Verneuil Vanina De Sells 3,117 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 3,117 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total transaction of $29,705.01. Following the completion of the sale, the executive vice president directly owned 126,682 shares in the company, valued at approximately $1,207,279.46. The trade was a 2.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Wednesday, February 25th, Verneuil Vanina De sold 13,700 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.82, for a total value of $134,534.00.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $33,115.25.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $9.09 on Friday. The business has a 50 day simple moving average of $7.01 and a 200 day simple moving average of $6.07. The company has a market capitalization of $1.27 billion, a PE ratio of -2.88 and a beta of 1.69. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business’s revenue was up 417.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.76) earnings per share. Equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VIR. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Vir Biotechnology in a report on Thursday. Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research report on Tuesday. Evercore reiterated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Finally, Morgan Stanley raised their target price on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.89.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently made changes to their positions in the company. ARCH Venture Management LLC acquired a new stake in Vir Biotechnology in the second quarter worth about $65,100,000. GSK plc bought a new position in shares of Vir Biotechnology in the 4th quarter valued at about $51,562,000. State Street Corp lifted its holdings in Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after buying an additional 988,262 shares during the period. Orbimed Advisors LLC boosted its stake in Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock valued at $11,999,000 after acquiring an additional 132,466 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Vir Biotechnology by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock worth $14,041,000 after acquiring an additional 81,985 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.